Migraine Nasal Spray Market size was over USD 502.18 million in 2023 and is poised to cross USD 1.18 billion by the end of 2036, witnessing more than 6.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of migraine nasal spray is estimated at USD 529.5 million.
The market growth can be attributed to growing prevalence of migraine, backed by the increased stress, depression, sleep deprivation, and anxiety prevalent amongst the population. In fact, migraine is the third most common disease, and approximately 1 billion people suffer from migraine worldwide. Furthermore, scientists suggest that humans are facing extreme weather changes, which can aggravate their health, making diseases, such as, migraine a common phenomenon. According to the World Meteorological Organisation, [R1] the decade 2011-2020 was the warmest on record, and the year 2020 is among the three warmest years globally. The increasing adulteration in food, hormonal misbalance, and longer screen time are also major reasons behind the growing number of migraine patients. Scientists have also found that migraine is more pervasive in women owing to hormonal changes, as 8 out of 10 people with migraine are women. As the number of patients with migraine is increasing exponentially, people are seeking an efficient remedy to eradicate the excruciating pain, which is expected to expand the global migraine nasal spray market.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.8% |
|
Base Year Market Size (2023) |
USD 502.18 million |
|
Forecast Year Market Size (2036) |
USD 1.18 billion |
|
Regional Scope |
|
The global migraine nasal spray market is segmented by drug type into ergotamine dihydroergotamine, ketorolac, and zolmitriptan, out of which the zolmitriptan segment is anticipated to hold the largest share in the market over the forecast period on account of the low cost and higher efficiency of the drug. Also, the manufacturers of zolmitriptan have tried to nullify the side effects caused by the usage of migraine nasal spray making the product popular amongst people.
Our in-depth analysis of the global migraine nasal spray market includes the following segments
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Dosage
|
|
North America Market Statistics
Regionally, the global migraine nasal spray market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. North America industry is estimated to account for largest revenue share by 2036, impelled by increasing cases of migraine, raising awareness, and developing health care infrastructure. According to the report published in U.S. National Library for Medicine, migraine continues to be an important public health problem prevalent among 15.9% of all adults in the year 2018. Moreover, around 40% of US adults with migraine were unemployed in the same year. Hence, the governments in developed nations are addressing the disadvantages of migraines and making people aware of remedies, such as, migraine nasal spray, which is estimated to boost the market growth.
APAC Market Analysis
The migraine nasal spray market in the Asia Pacific region is expected to expand significantly over the forecast period. Highly populated countries such as India, China, and others, are estimated to offer a large consumer base for migraine nasal sprays, owing to the increasing cases of migraine in the region.
March 22, 2022: Impel NeuroPharma, the manufacturer of migraine nasal spray Trudhesa, presented drug performance data at the 2022 scientific meeting of the American Academy of Neurology. The latest data shows rapid and consistent migraine relief with Trudhesa treatment.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?